OnabotulinumtoxinA for chronic migraine: a critical appraisal
Rubesh Gooriah, Fayyaz Ahmed Department of Neurology, Hull Royal Infirmary, Kingston Upon Hull, UK Abstract: Chronic migraine (CM) is a severe disabling condition with a few available evidence-based management options. OnabotulinumtoxinA (onaBoNTA) is approved for use in a number of disorders. Its...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-06-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/onabotulinumtoxina-for-chronic-migraine-anbspcritical-appraisal-peer-reviewed-article-TCRM |